课题基金 / 基金详情

Mitochondrial Dysfunction in HAART: Point of Care Tests

Mitochondrial Dysfunction in HAART: Point of Care Tests
HAART 中的线粒体功能障碍:护理点测试
批准号:
7423846
负责人:
Michael F Marusich
金额:
$59.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2011-04-30
关键词:
AIDS/HIV problemAddressAdverse effectsAnti-HIV AgentsAntibioticsAntineoplastic AgentsAreaBedside TestingsBiogenesisBiological AssayBiological MarkersBiopsyBloodCanned FoodsCell physiologyCellsCheek structureClinicalClinical InvestigatorClinical ResearchContractsCountryData AnalysesDevicesDiabetes MellitusDiagnosisDiagnosticDiseaseDisease ManagementDrug FormulationsEarly DiagnosisEffectivenessEnrollmentEnzymesExhibitsFatty acid glycerol estersFriedreich AtaxiaFutureGenerationsGoalsGovernmentHemorrhagic ShockHighly Active Antiretroviral TherapyHome environmentImmunoassayInheritedLateralLifeLipoatrophyMalignant NeoplasmsMarketingMeasurementMeasuresMetabolicMetabolic DiseasesMitochondriaMitochondrial DiseasesMitochondrial ProteinsMonitorNeurodegenerative DisordersNormal RangeOxidative PhosphorylationParkinson DiseasePatient MonitoringPatientsPerformancePeripheralPeripheral Nervous System DiseasesPharmaceutical PreparationsPharmacologic SubstancePhasePhysiciansPilot ProjectsPregnancy TestsPreparationProcessProductionProteinsPublishingRelative (related person)ResearchResearch ContractsResourcesRiskSafetySamplingScreening procedureSepsisServicesSourceSwabSymptomsSystemTestingThailandTimeTimeLineTissue ExtractsTissue SampleToxic effectTreatment EffectivenessUrineVisualWhole BloodWorkZidovudinebasecompliance behaviorcopingdesigndetectorimprovedinstrumentmetabolic abnormality assessmentminimally invasivemitochondrial dysfunctionmolecular pathologynovel therapeuticsperipheral bloodpoint of careprototyperatiometrictoolurinary

项目摘要

项目成果

Michael F Marusich的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):用于治疗艾滋病毒/艾滋病的高效抗逆转录病毒疗法(HAART)具有严重的副作用,包括可能危及生命的线粒体毒性引起的代谢并发症,并限制了有效性和患者的依从性。不良代谢影响现在由熟练的临床医生管理,他们密切监测患者的临床症状并相应地调整治疗。然而,改进毒性的早期检测可以帮助医生控制副作用,减少对患者的风险,并避免出现临床症状,其中一些症状是持久的,只能部分可逆。线粒体氧化磷酸化(OXPHOS)蛋白水平是HAART毒性早期生物标志物的良好候选物,因为OXPHOS通常产生>90%的细胞能量。在临床研究中,I期开发的一套试纸免疫测定试验表明,外周脂肪和外周血单核细胞(PBMCs)中的OXPHOS缺陷与haart诱导的脂肪萎缩有关。这些测试是高度定量的,但简单快速,因为基本平台类似于许多应用中使用的平台,如家用验孕包。第二阶段的工作将通过增加一个内部负载控制来改进测试,以方便比率读数,并将油尺整合到坚固的一次性卡带中。这些改进将简化样品处理需求和数据分析,允许在护理点应用。研究还表明,这些测试可以很容易地用于取样组织,包括脸颊拭子、手指刺全血和尿液沉积物。II期工作包括临床研究,以确定这些容易取样的组织中OXPHOS缺陷是否与HAART不良代谢作用(脂肪萎缩和周围神经病变)的临床症状相关,如果是这样,OXPHOS缺陷是否在我们的初步研究中强烈建议的症状发作之前出现。确认的结果将极大地支持测试的效用,以帮助指导治疗,以尽量减少HAART的长期副作用。此外,由于线粒体能量产生对细胞功能至关重要,OXPHOS疾病还涉及许多其他疾病。第一代OXPHOS试纸已经被用于遗传性线粒体疾病、神经退行性疾病(PD和共济失调)、败血症和癌症等其他代谢疾病的研究。这些测试在这些领域和其他领域都具有潜在的诊断/治疗效用。这些测试现在也被用于制药合同药物安全筛选,以确定新的治疗药物的有丝分裂毒性副作用,不仅包括新的抗逆转录病毒药物,还包括许多其他药物,如抗生素和抗癌药物,这些药物的有丝分裂毒性是一种确定的风险。因此,这些测试将在III期商业化和上市,作为:1)诊断/治疗辅助工具,帮助指导HAART和其他代谢疾病,2)研究HAART和其他线粒体疾病的不良代谢影响的分子病理学研究工具,以及3)用于药物安全性筛选的线粒体毒性和线粒体生物发生测定。相关性:用于治疗艾滋病毒/艾滋病的高效抗逆转录病毒疗法(HAART)具有严重的不良副作用,可能危及生命并限制治疗效果。我们正在制作简单、廉价的试纸测试,可与容易获得的样本(口腔拭子、手指刺血和尿液)一起使用,以监测HAART的不良影响,并帮助指导治疗以尽量减少毒副作用。因为这些测试有助于测量病人分解和利用食物中能量的能力,它们也可以用来监测在许多其他情况下发生的类似干扰,包括帕金森病、癌症、败血症和遗传性疾病,也可以用来筛选类似毒性作用的新治疗药物,并避免在病人身上使用。
英文摘要
DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust therapies accordingly. However, improved earlier detection of toxicities could help physicians manage side effects with less risk to patients and avoid onset of clinical symptoms, some of which are persistent and only partially reversible. Mitochondrial Oxidative Phosphorylation (OXPHOS) protein levels are good candidates for early biomarkers of HAART toxicity as OXPHOS normally makes >90% of cellular energy. A set of dipstick immunoassay tests developed in Phase I have been used in clinical studies to show that OXPHOS deficits in both peripheral fat and Peripheral Blood Mononucleated Cells (PBMCs) correlate with HAART-induced lipoatrophy. The tests are highly quantitative, yet simple and rapid as the basic platform is similar to that used in many applications such as home-use pregnancy test kits. Phase II work will improve the tests by adding an internal loading control to facilitate ratiometric readout, and incorporating the dipsticks into robust single-use cassettes. The improvements will streamline sample processing needs and data analysis, allowing application at point of care. It has also been shown that the tests can be used with easily sampled tissues, including cheek swabs, fingerprick whole blood and urinary sediment. Phase II work includes clinical research to determine if OXPHOS deficits in these easily sampled tissues correlate with clinical symptoms of adverse metabolic effects of HAART (lipoatrophy and peripheral neuropathy) and if so, whether or not OXPHOS deficits precede onset of symptoms as strongly suggested in our pilot study. Confirmatory results would greatly support utility of the tests to help guide therapy to minimize long-term side effects of HAART. Moreover, because mitochondrial energy production is essential for cellular function, OXPHOS disorders are involved in many other conditions. The 1st generation OXPHOS dipstick tests are already being used in studies of inherited mitochondrial diseases, neurodegenerative disorders (PD and Friedreich s Ataxia), and other metabolic disorders such as sepsis and cancer. The tests have potential diagnostic/theranostic utility in each of these and other areas. The tests are also now being used in Pharmaceutical contract drug safety screening to identify mitotoxic side effects of new therapeutic drugs, including not just new antiretrovirals, but many other drugs such as antibiotics and anti-cancer drugs, for which mitotoxicity is an established risk. Therefore, the tests will be commercialized and marketed in Phase III as: 1) diagnostic/theranostic aids to help guide HAART and other metabolic conditions, 2) research tools to study the molecular pathology of the adverse metabolic effects of HAART and other mitochondrial disorders, and 3) mitotoxicity and mitochondrial biogenesis assays for Pharmaceutical drug safety screening.RELEVANCE: Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious adverse side-effects that can be life-threatening and limit effectiveness of treatment. We are making simple, inexpensive dipstick tests that can be used with easily obtained samples (cheek swab, fingerprick blood and urine) to monitor the adverse effects of HAART and help guide therapy to minimize toxic side-effects. Because the tests help measure a patient s ability to break down and use energy in food, they can also be used to monitor similar disturbances known to occur in many other conditions, including Parkinsons disease, cancer, sepsis and inherited diseases, and also to screen new therapeutic drugs for similar toxic effects and avoid their use in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Simultaneous Diagnosis of Dengue and Prognosis of Severe Dengue with a Single Point-of-Care Test
  • 批准号:
    10475305
  • 项目类别:
  • 资助金额:
    $29.99万
  • 财政年份:
    2021
  • 负责人:
    Michael F Marusich
  • 依托单位:
Simultaneous Diagnosis of Dengue and Prognosis of Severe Dengue with a Single Point-of-Care Test
  • 批准号:
    10324527
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Michael F Marusich
  • 依托单位:
Mitochondrial dysfunction in HAART: Point of care tests
  • 批准号:
    6893169
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2005
  • 负责人:
    Michael F Marusich
  • 依托单位:
Kits to Quantitate and Analyze Mitochondrial Proteins
  • 批准号:
    6787462
  • 项目类别:
  • 资助金额:
    $14.0万
  • 财政年份:
    2004
  • 负责人:
    Michael F Marusich
  • 依托单位:
海外基金